Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.

@article{Quintana2012EffectsOL,
  title={Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.},
  author={Adrien Quintana and V{\'e}ronique Sgambato-Faure and Marc Savasta},
  journal={Neurobiology of disease},
  year={2012},
  volume={48 3},
  pages={379-90}
}
Dyskinesia is a major side effect of chronic levodopa (L-DOPA) administration, the reference treatment for Parkinson's disease (PD). High-frequency stimulation of the subthalamic nucleus (STN-HFS) alleviates parkinsonian motor symptoms and indirectly improves dyskinesia by decreasing L-DOPA requirement. However, inadequate stimulation can also trigger… CONTINUE READING